Trial Profile
A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Ibrutinib; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 30 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Oct 2022.
- 12 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2019.